An original stem cell study provides insight into Klinefelter syndrome.

Published Date: 05 Apr 2023

Scientists have conducted a first-of-its-kind study in a collaboration between King Abdullah University of Science and Technology (KAUST), King Abdulaziz University, Jeddah (KAU), and King Abdulaziz University Hospital, Jeddah (KAUH).

Read Full News

Latest News

Ultra-Rapid U500 Aspart AT278 Aids High-Dose T2D Therapy Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent clinical successes of ultra-fast-acting insulin AT278.

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

ZUPREME-2: Petrelintide Outperforms Placebo for Weight Loss in T2D and Obesity

ZUPREME-2: Petrelintide Outperforms Placebo for Weight Loss in T2D and Obesity

New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity

New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity

8 Endocrinology Headlines You Missed in Q3 2026

8 Endocrinology Headlines You Missed in Q3 2026

Investigational Rapid-Acting U500 Insulin Maintains Efficacy Regardless of BMI Thomas Pieber, MD

Thomas Pieber, MD, discusses a recent phase 1 trial investigating AT278’s efficacy in patients with T2D and obesity compared to other fast-acting insulins.

Todays Updates

Tailoring Pulmonary Rehab to Close the COPD Gap, With Omid Pourshahid, MD Omid Pourshahid, MD

At CHEST 2026, Pourshahid argued for matching patients to center-based, hybrid, or virtual pulmonary rehab based on a structured assessment.

Virtual Pulmonary Rehab and Matched Care, With Omid Pourshahid, MD Omid Pourshahid, MD

Omid Pourshahid, MD, MPH, discusses Medicare coverage for virtual pulmonary rehab and a matched-care pathway for center-based, hybrid, or virtual programs.

Experts Examine Biologic Coverage in Asthma and COPD

Experts Examine Biologic Coverage in Asthma and COPD

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated Marco Meglio

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.

New Phase 2 Trial Evaluates Fenebrutinib Dosing in Children With Relapsing MS Louie Pasculli

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Todays Updates

Tailoring Pulmonary Rehab to Close the COPD Gap, With Omid Pourshahid, MD Omid Pourshahid, MD

At CHEST 2026, Pourshahid argued for matching patients to center-based, hybrid, or virtual pulmonary rehab based on a structured assessment.

Virtual Pulmonary Rehab and Matched Care, With Omid Pourshahid, MD Omid Pourshahid, MD

Omid Pourshahid, MD, MPH, discusses Medicare coverage for virtual pulmonary rehab and a matched-care pathway for center-based, hybrid, or virtual programs.

Experts Examine Biologic Coverage in Asthma and COPD

Experts Examine Biologic Coverage in Asthma and COPD

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated Marco Meglio

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.

New Phase 2 Trial Evaluates Fenebrutinib Dosing in Children With Relapsing MS Louie Pasculli

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Latest News

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent clinical successes of ultra-fast-acting insulin AT278.

Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era

ZUPREME-2: Petrelintide Outperforms Placebo for Weight Loss in T2D and Obesity

New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity

8 Endocrinology Headlines You Missed in Q3 2026

Thomas Pieber, MD, discusses a recent phase 1 trial investigating AT278’s efficacy in patients with T2D and obesity compared to other fast-acting insulins.

News All Time

FDA Accepts NDA for Encaleret for Autosomal Dominant Hypocalcemia Type 1 Ryan Livingston

If approved, encaleret will be the first treatment specifically indicated for this underrepresented patient population.

Retatrutide Meets Phase 3 Weight-Loss Endpoints in 2 Obesity Trials Ryan Livingston

Retatrutide met 80-week weight-loss endpoints in TRIUMPH-2 and TRIUMPH-3, prompting a planned FDA submission in Q1 2027.

Medically Tailored Groceries Improve Blood Sugar Control, Nutrition in T2D Ryan Livingston

A recent study from Kaiser Permanente has indicated substantial HbA1c improvements among patients receiving food-based support.

5 Endocrinology Headlines You Missed in July 2026 Ryan Livingston

New Drug Applications and key trial readouts punctuated July for endocrinology, with treatments for hypocalcemia, diabetes, and more.

Continuous Glucose Monitoring in Type 2 Diabetes, With John Anderson, MD John Anderson, MD

Anderson discusses recent advancements in CGM technology, as well as the myriad behavioral and clinical benefits of CGM use in T2D with or without insulin.

Secret Shopper Study Reveals GLP-1 Telehealth Gaps Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the risks of ordering GLP-1 RAs online.

TRIUMPH-2: Retatrutide Reduces Weight, A1C in Patients With Obesity Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, discuss the topline results of the TRIUMPH-2 trial of retatrutide.

Ascendis Reports 78-Week Data From COACH Trial for Achondroplasia Ryan Livingston

Combination therapy with navepegritide and lonapegsomatropin has demonstrated its efficacy in improving mean annualized growth velocity in pediatric patients.

Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3 Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss topline data from the TRIUMPH-3 trial of retatrutide.

500,000 Patients With Diabetes May Lose Healthcare Under New Medicaid Legislation Ryan Livingston

Limits to provider taxes used to fund Medicaid programs, as well as increased eligibility requirements and cost-sharing obligations, may make insurance inaccessible.

Insulin Icodec Now Available for Type 2 Diabetes in US Ryan Livingston

Novo Nordisk's once-weekly insulin icodec-abae (Awiqli) has launched nationwide for adults with type 2 diabetes.

VESALIUS-CV: Evolocumab Prevents Cardiovascular Disease in High-Risk Diabetes Marc P. Bonaca, MD, MPH

The phase 3 trial of evolocumab showed cardioprotective effects in patients without prior MI or stroke, regardless of qualifying atherosclerosis or background therapy.

Tirzepatide Demonstrates Cardioprotective Effects in T2D With ASCVD Ryan Livingston

In a trial comparing tirzepatide initiation with sitagliptin, the GLP-1/glucose dual agonist displayed greater reductions in major cardiovascular events.

Diabetes Dialogue: Tech, Screening, and Care Highlights from ADCES 2026 Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, Natalie Bellini, DNP, FNP, BC-ADM, CDCES

Diabetes Dialogue hosts recap ADCES26 highlights on insulin delivery tech, CKM care, C-peptide science, ketone monitoring, and hypercortisolism screening.

Avexitide Reduces Hypoglycemic Events in Phase 3 LUCIDITY Trial for PBH Ryan Livingston

The phase 3 trial showed a 55% reduction in Level 2 and Level 3 hypoglycemic events versus placebo, meeting all secondary endpoints.

The HCPFive: Top News for Healthcare Providers from the Week of 08/16 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including a new lerodalcibep FDA approval and phase 3 avexitide data in post-bariatric hypoglycemia.

Recommended News For You

More Data Back Teclistamab for Autoimmune Disease

C/EBP? works in tandem with MYB to sustain AML cells' oncogenic program.

MRD Tied to PFS in Lymphoma Patients on Epcoritamab

Shorter, less intense regimen still effective for HPV-linked throat cancer, study shows

Screening tests that are non-invasive show promise in detecting colorectal cancer.

The FDA approves alexinib as an adjuvant treatment for non-small cell lung cancer.

The standard for high-risk prostate cancer is supported by a study using high-dose RT and long-term ADT.

Recommended Articles For You

Clinical Pharmacology of Drug Exposure During Long-Term Cancer Survivorship 

Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides 

Unlocking the Mysteries of Rhabdomyoma: A New Hope for Treatment 

The Benefits and Risks of Transurethral Resection of Bladder Tumor  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

J. Craig Venter, Who Won the Race to Sequence the Human Genome, Dies at 79

2.

Three out of ten breast cancers detected between screenings, study finds

3.

MRD Tied to PFS in Lymphoma Patients on Epcoritamab

4.

AI can identify women at risk of breast cancer years in advance: Study

5.

Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.

1.

Interpreting Iron Studies: What Your Blood Results Really Mean 

2.

The Mysterious Pain of Scrotal Hematoma: A Guide to Diagnosis and Treatment

3.

Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025

4.

Digital Oncology Ecosystems Integrating Longitudinal Patient Trajectories: Transforming Cancer Care through Data-Driven Innovation

5.

Preventing Treatment-Related Secondary Malignancies: Evidence-Based Strategies for Clinical Practice

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Navigating the Complexities of Ph Negative ALL - Part IV

2.

Navigating the Complexities of Ph Negative ALL - Part XVI

3.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

4.

Signs and Symptoms of Leukemia

5.

The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot